Overview

SER150 vs Placebo in Diabetic Kidney Disease

Status:
Recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
This study is to assess the efficacy, safety and pharmacokinetic (PK) of SER150 administered for 12 weeks as a 15 mg twice a day (BID) dose in participants with type 2 diabetes (T2D) and macroalbuminuria in treatment with either an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor antagonist (ARB).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Serodus ASA